Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia

Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia

Aggressive therapy-resistant and refractory acute myeloid leukemia (AML) has an extremely poor outcome. By analyzing a large number of genetically complex and diverse, primary high-risk poor-outcome human AML samples, we identified specific pathways of therapeutic vulnerability. Through drug screens...

Full description

Bibliographic Details
Main Authors: Hashimoto, M, Saito, Y, Nakagawa, R, Ogahara, I, Takagi, S, Takata, S, Amitani, H, Endo, M, Yuki, H, Ramilowski, JA, Severin, J, Manabe, R-I, Watanabe, T, Ozaki, K, Kaneko, A, Kajita, H, Fujiki, S, Sato, K, Honma, T, Uchida, N, Fukami, T, Okazaki, Y, Ohara, O, Shultz, LD, Yamada, M, Taniguchi, S, Vyas, P, de Hoon, M, Momozawa, Y, Ishikawa, F
Format: Journal article
Language:English
Published: Springer Nature 2021

Similar Items